Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Nov 27, 2012 10:39am
146 Views
Post# 20648652

RE: Brigus Gold , Goldstream Buyback

RE: Brigus Gold , Goldstream Buyback

Josa:

 

RE"If 4% of the buyback equates to 24.4 million dollars, would it be fair to say that a 100% is 25 times 24.4 equals 610 million dollars."

 

[S] At the risk of attracting the venom of the resident experts without (face to boardroom) mining experience I choose the do my (Q & D ... back of the envelope) analysis as follows:

 

1.  Assume steady state production of 100 000 Au equivalent OZS/year.

 

2. Pre-buyback saw 88% (88 000 Ozs) going to BRD directly (@ $1 700 & $ 800 COP) = ~$ 79.2 mln

2.1 From the 12% Stream BRD would get ($500 from SSL and $800 COP) = NEGATIVE $3.6 mln.

 

3.0 Buyback of 50% of the 12% stream would (by extension) mean ...

 

3.1 The remaining 6% SSL would cost BRD NEGATIVE $ 1.6 mln.

3.2 The repurchased 6% will provide an absolute benefit of $7.2 mln (6,000 OZ @ $1 200)

3.2.1 Meaning BRD will not be subsidizing a $300 shortfall for each streaming ounce. ( $1.8 mln).

3.2.2 BRD will have a NET benefit of $900 per ounce (6 000 x $900) = $ 5.4 mln.

 

BOTTOM LINE:

Instead of being NEGATIVE $3.6 mln (ANNUALLY) for the original (12%) stream the repurchase of 50% (6%) will be bringing in to BRD's coffers $5.4 mln ANNUALLY (can now use NPV calcs for 10 years at x%).

 

NET change/impact to the BRD bottom line is $7.2 mln ANNUALLY.

 

BWDIK? NO STREAM ON THE GREY FOX property.  TA does not reflect infill drill info and the production and overhead savings from the incremental production from GF. 

 

Hope this helps.

 

Cheers

Stanley

 

Bullboard Posts